Notably, gene mutations of RUNX1 and NRAS were more frequent in GCNT2high group (both of the p-values were 0.02), and the CEBPA gene mutation, regarded as a favorable biomarker in AML, tended to be more frequent in GCNT2LOW group (P = 0.09), however, the ratio of the patient with FLT3 mutation more enriched in GCNT2LOW group, as unexpected. This evidence concerns the gene CEBPA and acute myeloid leukemia.